Filing Flows › Karyopharm Therapeutics (KPTI) › Q2 2025
Karyopharm Therapeutics (KPTI) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 11, 2025
Karyopharm Therapeutics (KPTI) reported revenue of $37.9M for the second quarter 2025 (Q2 2025), -11% from a year earlier and +26% from the quarter before. Operating margin was -64.3%, net loss $37.3M (98.2% of revenue).
Karyopharm Therapeutics, Q2 2025: revenue $37.9M (-11% year over year), operating margin -64.3%, net loss $37.3M, operating cash flow −$18.7M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $37.9M | +26% | -11% |
| Operating profit | −$24.4M | — | — |
| Net earnings | −$37.3M | — | — |
| Operating cash flow | −$18.7M | — | — |
What changed
Revenue was $37.9M in Q2 2025, down 11% year over year and up 26% from the previous quarter. Product was the largest line at 78% of revenue. License and Other lost $6.5M year over year (down 44%), 134% of the total change.
Operating costs exceeded revenue by $24.4M, an operating margin of -64.3%. Total costs fell 12% while revenue fell 11%. The quarter ended with a net loss of $37.3M, wider than the previous quarter's $23.5M loss.
Operating cash flow was −$18.7M. Non-cash charges added back $78K of depreciation and $3.8M of share-based compensation. Working capital and other items added $14.7M.
Questions
What was Karyopharm Therapeutics' revenue in the second quarter 2025?
Karyopharm Therapeutics (KPTI) reported revenue of $37.9M for the second quarter 2025 (Q2 2025), -11% from a year earlier and +26% from the quarter before.
Was Karyopharm Therapeutics profitable in the second quarter 2025?
Operating loss was $24.4M (-64.3% of revenue) and net loss $37.3M.